These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37328062)

  • 1. Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: A network meta-analysis of randomised clinical trials.
    Lin MH; Shen YC; Cheng HY; Teng CK; Chen WC; Lin YC; Hung CC
    J Glob Antimicrob Resist; 2023 Sep; 34():46-58. PubMed ID: 37328062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials.
    Chen TY; Hsu CK; Shih SC; Weng TS; Tang HJ; Lai CC
    Int J Antimicrob Agents; 2023 Aug; 62(2):106844. PubMed ID: 37160243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of efficacy and safety of doripenem for treating bacterial infections.
    Qu XY; Hu TT; Zhou W
    Braz J Infect Dis; 2015; 19(2):156-62. PubMed ID: 25636188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options.
    Golan Y
    BMC Infect Dis; 2015 Aug; 15():313. PubMed ID: 26243291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
    Popejoy MW; Long J; Huntington JA
    BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
    Syed YY
    Drugs; 2021 Sep; 81(13):1559-1571. PubMed ID: 34427896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel β-lactam/β-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials.
    Chen M; Zhang M; Huang P; Lin Q; Sun C; Zeng H; Deng Y
    Expert Rev Anti Infect Ther; 2018 Feb; 16(2):111-120. PubMed ID: 29343141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of carbapenems versus alternative antimicrobials for treating complicated urinary tract infections caused by antimicrobial-resistant Gram-negative bacteria: protocol for a systematic review and meta-analysis.
    Maeda M; Hasegawa T; Noma H; Ota E
    BMJ Open; 2023 Apr; 13(4):e069166. PubMed ID: 37085310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
    Kong W; Deng T; Li S; Shu Y; Wu Y
    BMC Infect Dis; 2023 Apr; 23(1):256. PubMed ID: 37085768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection: A systematic review and network meta-analysis.
    Tan X; Pan Q; Mo C; Li X; Liang X; Li Y; Lan Y; Chen L
    Medicine (Baltimore); 2020 Jan; 99(2):e18769. PubMed ID: 31914101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.
    Das S; Li J; Riccobene T; Carrothers TJ; Newell P; Melnick D; Critchley IA; Stone GG; Nichols WW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
    Rice DA; Kaniga K; Lee M; Redman R
    Int J Antimicrob Agents; 2013 Apr; 41(4):388-92. PubMed ID: 23410792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections-A meta-analysis of randomized controlled trials.
    Cheng IL; Chen YH; Lai CC; Tang HJ
    Int J Antimicrob Agents; 2020 Feb; 55(2):105858. PubMed ID: 31786332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
    Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenems vs tigecycline for the treatment of complicated intra-abdominal infections: A Bayesian network meta-analysis of randomized clinical trials.
    Chen L; Liang X; Jiang J; Li X; Li Y
    Medicine (Baltimore); 2019 Oct; 98(40):e17436. PubMed ID: 31577763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.